Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 248

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 1B
Chunk 248
---
2023

    10.29+
     
    Amendment No. 6 to Commercial Manufacturing Services Agreement between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc. dated December 30, 2023
     
    10-K

    10.29
     
    03/28/2024

    10.30+
     
    Amendment No. 7 to Commercial Manufacturing Services Agreement between Atara Biotherapeutics, Inc. and Charles River Laboratories, Inc. dated January 31, 2024
     
    10-K

    10.30
     
    03/28/2024

    10.31+
     
    Amendment No. 8 to Commercial Manufacturing Services Agreement between Atara Biotheraputics, In. and Charles River Laboratories, Inc. dated March 31, 2024
     
    10-Q

    10.1
     
    05/09/2024

    10.32+
     
    Amendment No. 9 to Commercial Manufacturing Services Agreement between Atara Biotheraputics, In. and Charles River Laboratories, Inc. dated April 30, 2024
     
    10-Q

    10.1
     
    08/12/2024

136

    Exhibit

    Incorporated by Reference
     
    Filed

    Number
     
    Exhibit Description
     
    Form

    Exhibit
     
    Filing Date
     
    Herewith

    10.33+
     
    Amendment No. 10 to Commercial Manufacturing Services Agreement between Atara Biotheraputics, In. and Charles River Laboratories, Inc. dated May 31, 2024
     
    10-Q

    10.2
     
    08/12/2024

    10.34+
     
    Amended and Restated Commercialization Agreement by and between Atara Biotherapeutics, Inc. and Pierre Fabre Medicament dated October 31, 2023
     
    10-K

    10.31
     
    03/28/2024

    10.35*
     
    Atara Biotheraputics, Inc. 2024 Equity Incentive Plan
     
    S-8

    4.4
     
    6/11/2024